Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.

Autor: Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA mkonople@mdanderson.org., Thall PF; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yi CA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Coveler A; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA., Bueso-Ramos C; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Benito J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konoplev S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gu Y; Auckland Cancer Society Research Centre, University of Auckland, NZ, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Faderl S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Thomas D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cortes J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kornblau S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nguyen HQ; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Feliu J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lu H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wei C; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wilson WR; Auckland Cancer Society Research Centre, University of Auckland, NZ, USA., Melink TJ; Proacta Inc., La Jolla, CA, USA., Gutheil JC; Proacta Inc., La Jolla, CA, USA., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Estey EH; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: Haematologica [Haematologica] 2015 Jul; Vol. 100 (7), pp. 927-34. Date of Electronic Publication: 2015 Feb 14.

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.

Autor: McKeage MJ; Auckland Cancer Society Research Centre and Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, The University of Auckland, 89 Grafton Rd, Auckland, New Zealand. m.mckeage@auckland.ac.nz, Gu Y, Wilson WR, Hill A, Amies K, Melink TJ, Jameson MB

Publikováno v: BMC cancer [BMC Cancer] 2011 Oct 07; Vol. 11, pp. 432. Date of Electronic Publication: 2011 Oct 07.

A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity.

Autor: Patel K; Faculty of Medical and Health Sciences, Auckland Cancer Society Research Centre, The University of Auckland, Private Bag 92019, Auckland, New Zealand., Choy SS, Hicks KO, Melink TJ, Holford NH, Wilson WR

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2011 May; Vol. 67 (5), pp. 1145-55. Date of Electronic Publication: 2010 Aug 04.